Cancer Combo Collaborations Held Back By IP, Complexity – PSA Panelists
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite strides in recent years toward more cross-company collaborations to test cancer drugs in combination, most deals remain short-term, early-stage clinical partnerships, according to panelists at the Pharmaceutical Strategy Conference.
You may also be interested in...
Merck’s Keytruda Opens Door, But Combination Trials Could Unlock Efficacy
FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.
Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Sanofi Paid $14.6bn In Rebates In 2020; Net Prices Were Down
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: